Public Release: 

Insilico Medicine to present predictors of drug-induced cardiotoxicity at BioData EU 2018

InSilico Medicine, Inc.


IMAGE: Insilico Medicine presents predictors of drug-induced cardiotoxicity at BioData EU 2018. view more 

Credit: Insilico Medicine

Monday, November 19, 2018, Rockville, MD - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence is pleased to announce the talk of Polina Mamoshina, a senior research scientist at Insilico Medicine at the World's leading congress for big data in precision medicine - Biodata World Congress 2018.

The pharmaceutical industry currently generates large libraries of new chemical entities with the aim of selecting the most promising leads for the future clinical trials. Over the past several years, reports of unexpected drug-induced cardiotoxicity have led to the withdrawal of a number of drugs from the market. Being a member of the Computational Cardiovascular Science group at the Department of Computer Science, University of Oxford, on the 29th of November, 2018, Polina will present a joint research focused on how machine learning can be utilized for predicting a spectrum of drug-induced cardiovascular toxicities.

"Computational methods hold great potential to increase the productivity of drug discovery pipelines and could drive a more rational drug design. As the attrition rate due to cardiotoxicity remains high, there is a clear need for novel approaches capable of accommodating better safety testing. And in silico approaches that mimic response in humans could be the most promising alternative to the current preclinical testing," - said Polina Mamoshina a senior research scientist at Insilico Medicine

Biodata World 2018 brings together global heads of leading pharmaceutical companies and is created with the support of leading research institutes and the NHS. The congress will take place at Congress Center Basel, 28-29 November 2018.


Session details:

BioData World EU 2018
Day 2 - Thursday 29th November 2018 16:00
Talk: Predicting drug-induced cardiotoxicity through machine learning - AI vs Cardiotoxicity
Presenter: Polina Mamoshina, a Senior Research Scientist at Insilico Medicine

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceuticsfeatured several research papers by Insilico Medicine.

For further information, images or interviews, please contact:

Contact: Klug Gehilfer


Official website of the conference:

About Insilico Medicine, Inc Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.